GE Healthcare announced Feb. 25 the sale of its biopharmaceutical business to Danaher, and GE Chairman and CEO Larry Culp Jr. said the deal signified that a planned 2019 initial public offering (IPO) for GE Healthcare is now unlikely. GE is reportedly weighing its options following the deal, which casts off the biopharmaceutical business for $21.4 billion.
